I. **Asymptomatic** - Individuals who test positive for SARS-CoV-2 using a virologic test (i.e., a nucleic acid amplification test [NAAT] or an antigen test) but who have no symptoms that are consistent with COVID-19.

II. **Mild** – Individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) without shortness of breath, dyspnea, or abnormal chest imaging.

III. **Moderate** – Individuals who show evidence of lower respiratory disease during clinical assessment or imaging (e.g., shortness of breath, dyspnea, or abnormal chest imaging) and who have an oxygen saturation (SpO₂) ≥94% on room air at sea level.

IV. **Severe** – Individuals who have SpO₂ <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO₂/FiO₂) <300 mm Hg, a respiratory rate >30 breaths/min, or lung infiltrates >50%.

V. **Critical** – Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction.

---

Adapted from the NIH COVID-19 Treatment Guidelines:

1. Source: [https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/](https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/)

<table>
<thead>
<tr>
<th>Week</th>
<th>Dates</th>
<th>Count</th>
<th>I%</th>
<th>Count</th>
<th>II%</th>
<th>Count</th>
<th>III%</th>
<th>Count</th>
<th>IV%</th>
<th>Count</th>
<th>V%</th>
<th>Count</th>
<th>?%</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>10/30/22 - 11/5/22</td>
<td>2</td>
<td>6.1%</td>
<td>26</td>
<td>78.8%</td>
<td>1</td>
<td>3.0%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>4</td>
<td>12.1%</td>
<td>33</td>
</tr>
</tbody>
</table>